Key facts
- Humane Genomics’s last known valuation is $17.0M (Feb 2025).
- It has raised $8.1M; the latest was Seed Round ($8.0M) in Feb 2025.
- Notable investors include Y Combinator, Creative Destruction Lab, Mana Ventures, Gaingels, University of Toronto — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Humane Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Humane Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Humane Genomics
Developer of a synthetic virology platform designed to engineer oncolytic viral therapies for cancer treatment. The company's platform offers RNA-based viral therapies with selective infection, high lytic activity, and systemic delivery, enabling cancer patients to receive targeted, safe, and effective treatment with extended therapeutic duration.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2016
- Employees
- 6
- Website
- humanegenomics.com/
- Ownership
- Privately Held (backing)
Humane Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Humane Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Humane Genomics in its N-PORT filings yet. We sweep new filings monthly.